Cargando…

High pretreatment plasma D-dimer levels predict poor survival in patients with diffuse large B-cell lymphoma in the real world

BACKGROUND: Data on the role of pretreatment plasma D-dimer levels in the prognostic prediction of patients with diffuse large B-cell lymphoma (DLBCL) are limited. We here studied the potential prognostic roles of pretreatment plasma D-dimer levels in patients with DLBCL. METHODS: We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Haobo, Fan, Liping, Fu, Danhui, Lin, Qiuyan, Shen, Jianzhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797953/ https://www.ncbi.nlm.nih.gov/pubmed/35116497 http://dx.doi.org/10.21037/tcr-20-2908

Ejemplares similares

Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
por: Fan, Liping, et al.
Publicado: (2021)

Prognostic Significance of Blood Transfusion in Elderly Patients with Primary Diffuse Large B-Cell Lymphoma
por: Fan, Liping, et al.
Publicado: (2018)

Combination of Fresh Frozen Plasma and Cryosupernatant Plasma for Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura: A Single Institution Experience
por: Lin, Qiuyan, et al.
Publicado: (2019)

High Pretreatment D-Dimer Levels Correlate with Adverse Clinical Features and Predict Poor Survival in Patients with Natural Killer/T-Cell Lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

High pretreatment plasma D-dimer predicts poor survival of colorectal cancer: insight from a meta-analysis of observational studies
por: Lu, Shao-Long, et al.
Publicado: (2017)

Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era
por: Nair, Reena, et al.
Publicado: (2023)

Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma
por: Liu, Peng, et al.
Publicado: (2015)

High pretreatment plasma D-dimer levels predict poor prognosis in gastrointestinal cancers: A meta-analysis
por: Rong, Guoyi, et al.
Publicado: (2019)

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2023)

Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma
por: Phipps-Yonas, Hannah, et al.
Publicado: (2013)

Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer
por: Liu, Qianfei, et al.
Publicado: (2020)

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma
por: Nowakowski, Grzegorz, et al.
Publicado: (2022)

Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma
por: Wang, Xiaoyan, et al.
Publicado: (2023)

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi
por: Montgomery, Nathan D., et al.
Publicado: (2019)

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE
por: Ghesquieres, H., et al.
Publicado: (2022)

MicroRNA Profiling of Exosomes Derived from Red Blood Cell Units: Implications in Transfusion-Related Immunomodulation
por: Huang, Haobo, et al.
Publicado: (2019)

CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?
por: Liu, Yanquan, et al.
Publicado: (2020)

Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014)

High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension
por: Sakurai, Manabu, et al.
Publicado: (2015)

High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer
por: Fan, Shanshan, et al.
Publicado: (2018)

A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma
por: Liu, Peng, et al.
Publicado: (2019)

Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma
por: Kristensen, Lasse Sommer, et al.
Publicado: (2016)

Prognostic impact of pretreatment skeletal muscle index and CONUT score in diffuse large B-cell Lymphoma
por: Go, Se-Il, et al.
Publicado: (2023)

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
por: Moreno, Victor, et al.
Publicado: (2023)

Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
por: Song, Joo Y., et al.
Publicado: (2023)

Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma
por: Zheng, Weili, et al.
Publicado: (2021)

Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection
por: Tsai, Yu-Fen, et al.
Publicado: (2021)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China
por: Wang, Shuo, et al.
Publicado: (2021)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients
por: Marino, Dario, et al.
Publicado: (2022)

Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
por: Gupta, Varsha, et al.
Publicado: (2022)

Prognostic significance of Epstein–Barr virus DNA detection in pretreatment serum in diffuse large B‐cell lymphoma
por: Okamoto, Akinao, et al.
Publicado: (2015)

Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP
por: Wang, Jing, et al.
Publicado: (2016)

High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma
por: Fan, Liping, et al.
Publicado: (2017)

Impact of Qi-Invigorating Traditional Chinese Medicines on Diffuse Large B Cell Lymphoma Based on Network Pharmacology and Experimental Validation
por: Huang, Qian, et al.
Publicado: (2021)

MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection
por: Liu, Zhihe, et al.
Publicado: (2017)

Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome
por: Qazi, Sanjive, et al.
Publicado: (2023)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

Contrast-Enhanced Ultrasound Parameters and D-Dimer: New Prognostic Parameters for Diffuse Large B-Cell Lymphoma
por: Duan, Shaobo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_71guljq9pktmqsfuutijc1308v